A Clinical Study of Treating Influenza With Liugan Shuangjie Heji
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Yang - Jiao, MD
- Phone Number: +86 13601016612
- Email: Yangjiao2013@sina.cn
Study Contact Backup
- Name: Zhisong - Wu, MD
- Phone Number: +86 13811578627
- Email: wuzhisong1220@163.com
Study Locations
-
-
-
Beijing, China, 100078
- Recruiting
- Dongfang Hospital Affiliated to Beijing University of Chinese Medicine
-
Contact:
- Yang Jiao, MD
- Phone Number: +86 13601016612
- Email: Yangjiao2013@sina.cn
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The disease in flu season of flu, in line with the western medicine clinical diagnostic criteria for influenza;
- All influenza patients with TCM syndrome differentiation for the table is cold in the exterior and heat in the interior;
- The course of the disease within 48 hours, the axillary temperature is 38.0 degree or higher;
- Aged between 18 to 65 years;
- Voluntary and signed informed consent.
Exclusion Criteria:
- The first time to see a doctor Have used traditional Chinese medicine, or antiviral drugs;
- Routine blood WBC is greater than the upper limit of normal;
- Chest X-ray examination with inflammatory exudation images;
- With cardiovascular, liver, kidney and hematopoietic system such as severe primary disease, immunodeficiency disease, cancer, mental illness, without self-knowledge, liver and kidney function significantly abnormal liver meritorious service is more than 1.5 times higher than normal;
- Pregnancy, nursing mothers, and allergic constitution;
- Participated in clinical subjects for nearly three months.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Liugan Shuangjie Heji Group
Liugan Shuangjie Heji, take orally, 4 times a day, 100 ml each time (i.e. two doses per day), for a course of five days.
|
|
|
Active Comparator: Shufeng Jiedu Capsule Group
Shufeng Jiedu Capsule, take orally, 3 times a day, 4 capsules each time, for a course of five days.
|
|
|
Active Comparator: Oseltamivir Phosphate Capsule Group
Oseltamivir Phosphate Capsule, take orally, 2 times a day, 75 mg each time, for a course of five days.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
time from the medicine intake to 0.5℃ drop of body temperature
Time Frame: five days
|
five days
|
|
time for the body temperature to return to normal
Time Frame: five days
|
five days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Yang - Jiao, MD, Dongfang Hospital Beijing University of Chinese Medicine
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2013BAI13B021
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.